Stefan H. E. Kaufmann How Can We Improve the Existing Vaccine for Tuberculosis to Combat the Growing Number of Multi-Resistant Strains?
© Maximilian Dörrbecker
Max Planck Society
"The Max Planck Society is Germany's most successful research organization. Since its establishment in 1948, no fewer than 18 Nobel laureates have emerged from the ranks of its scientists, putting it on a par with the best and most prestigious research institutions worldwide. The more than 15,000 publications each year in internationally renowned scientific journals are proof of the outstanding research work conducted at Max Planck Institutes – and many of those articles are among the most-cited publications in the relevant field." (Source)
Max Planck Institute for Infection Biology
"The Max Planck Institute for Infection Biology was founded in 1993. The Institute commenced its operation in a provisional laboratory facility and a small group of scientists that has greatly expanded over the years, and relocated to an especially built facility in summer 2000."
"Infectious diseases continue to be the number one cause of death world-wide. Nearly one third of the cases of death caused by infectious diseases are attributable to "the big three", namely AIDS, malaria and tuberculosis.
In addition, new infectious diseases are arising and proving themselves to have major effects on society, such as Helicobacter pylori, the etiologic agent of infectious gastritis, or Chlamydia, the causative agents of various infections. Efficacious vaccines against most infectious agents are not available up to date, at the same time, the potential of available vaccines has been exhausted. The development and widespread use of antibiotics and other medications have contributed to the rise and spread of resistant strains.
Multidisciplinary research into the molecular and cellular mechanisms of infection is not only basic science, but also applied research essential for the development of novel preventative and therapeutic measures against infections, directly affecting the health and social problems of the present and future.
The Institute employs multi-disciplinary approaches to infection biology, comprising concepts and methodologies of molecular genetics, immunology, cell biology, epidemiology, clinical research and protein chemistry. The Institute promotes the applications of its research towards paving the way for the design of rational measures of control of infectious diseases." (Source)
Each year 1.5 million people die of tuberculosis thus making it the number one killer of all contagious diseases. With the number of multi-resistant tuberculosis growing, currently available treatments are no longer as effective as they used to be. The existing vaccine does not protect against pulmonary tuberculosis which is the most common form of the disease and easily transmittable. In this video, STEFAN H. E. KAUFMANN describes how this existing vaccine was modified to trigger an additional component of the cellular immune response. The researchers showed that it achieved profound reduction of bacterial load in the lung and an excellent safety profile in preclinical studies. The vaccine candidate is currently undergoing clinical trials to be approved for humans.
LT Video Publication DOI: http://dx.doi.org/10.21036/LTPUB10207
Increased Vaccine Efficacy Against Tuberculosis of Recombinant Mycobacterium Bovis Bacille Calmette-Guerin Mutants that Secrete Listeriolysin
- Leander Grode, Peter Seiler, Sven Baumann, Jürgen Hess, Volker Brinkmann, Ali Nasser Eddine, Peggy Mann, Christian Goosmann, Silke Bandermann, Debbie Smith, Gregory J. Bancroft, Jean-Marc Reyrat, Dick van Soolingen et al
- The Journal of Clinical Investigation
- Published in 2005